<DOC>
	<DOCNO>NCT01386554</DOCNO>
	<brief_summary>The purpose study provide nephrologists additional clinical evidence regard efficacy safety Acthar subject treatment-resistant idiopathic membranous nephropathy . Approximately sixty ( 60 ) subject randomize double-blind , parallel-group , placebo-controlled , multicenter study compare Acthar Placebo administer 2 time per week 24-week treatment period follow 24-week observation period . The primary objective study assess proportion treatment-resistant subject ( define subject either response suffer relapse achieve partial response recent standard treatment regimen ) complete partial remission proteinuria nephrotic syndrome due idiopathic membranous nephropathy 24 week treatment .</brief_summary>
	<brief_title>Acthar Treatment Proteinuria Membranous Nephropathy Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>For complete list inclusion exclusion criterion , please refer contact . Male female subject ≥18 year age , screen Visit 1 : . If potential subject &gt; 75 year age , discussion investigator Medical Monitor must take place ; Body mass index ≤40 kg/m2 , screen Visit 1 ; A history nephrotic syndrome due iMN confirm documented result renal biopsy perform within 4 year prior screen Visit 1 : . If biopsy perform 48 year prior screen , subject sign symptom diabetes clinical diagnosis could suggest change renal histology opinion investigator Medical Monitor , subject eligible . Renal target disease requirement : 1 . Total urine protein ≥3.0g ( ≥3000mg ) 24hour urine return Visit 1A , AND . 2 . An estimated glomerular filtration rate ( eGFR ) value &gt; 25mL/min/1.73m2 Visit 1A ( calculate use abbreviated Modification Diet Renal Disease [ MDRD ] equation . Any prior course least 1 month treatment ≥1 immunosuppressant therapy ( y ) iMN : 1 . Subjects must follow least 3 month treatment prior screen exception rituximab cytotoxic base therapy , followup period 6 month treatment . If followup determine subject achieve complete partial remission suffer relapse achieve partial remission , subject eligible study . 2 . If investigator 's opinion , subject enrol prior meeting followup period criterion decrease proteinuria longer occur , discussion investigator Medical Monitor must take place approval enter screen . History treatmentresistant iMN define either remission suffer relapse achieve partial remission recent standard treatment regimen define Definition Response Status Table despite treatment least 1 month treatment prior therapy iMN . Note follow : . If subject treat prior standard therapy longer retreat component therapy , regardless whether complete partial remission achieve , subject may eligible , approval Medical Monitor require . . For example , early discontinuation standard therapy occur serious adverse event ( Grade 3 4 ) treatment , regardless whether partial complete remission achieve , subject may eligible . b . If ( ) apply , subject either partial complete remission recent treatment regimen , subject eligible . c. If ( ) apply , subject achieve partial remission recent treatment regimen , later relapse occur , subject eligible . Antihypertensive treatment include use ACE inhibitor and/or ARB : . Unless history intolerance ACE inhibitor ARB therapy , subject must treat least one agent . b . Treatment ACE inhibitor and/or ARB ≥3 month prior screen Visit 1A , stable maintenance dose ≥30 day prior randomization . c. If treat antihypertensive therapy , treatment duration ≥30 day stable maintenance dose ≥7 day prior screen Visit 1A . Blood pressure determine average ≥3 seat reading take ≥5 minute apart screen period Visit 1A : 1 . Mean systolic blood pressure ≤140 mmHg 2 . Mean diastolic blood pressure ≤80 mmHg . Therapies and/or medication : 1 . History previous use Acthar treatment nephrotic syndrome ; 2 . Prior sensitivity Acthar porcine protein product ; 3 . Planned treatment live live attenuate vaccine enrol study . Contraindication Acthar per Prescribing Information : scleroderma , osteoporosis , systemic fungal infection , ocular herpes simplex , recent surgery , history presence peptic ulcer , congestive heart failure , uncontrolled hypertension , primary adrenocortical insufficiency , adrenocortical hyperfunction . . For purpose study : `` history '' peptic ulcer define ≤6 month prior Visit 1A . Renal target disease exclusion : 1 . Subjects know diabetic nephropathy nephrotic syndrome due disease process idiopathic membranous nephropathy , 2 . Subjects require diagnostic interventional procedure require contrast agent must delay screening/randomization least 7 day . History Systemic Lupus Erythematosus . Type 1 Type 2 diabetes mellitus ( prior diagnosis gestational diabetes mellitus exclusion ) . History Deep Vein Thrombosis ( DVT ) ≤6 month prior screen Visit 1A . Presence renal vein thrombosis : 1 . Known current diagnosis ultrasound , magnetic resonance imaging ( MRI ) compute tomography scan ; 2 . Signs symptoms consistent occurrence acute renal vein thrombosis ( hematuria combination flank pain &gt; 30 % unexplained acute rise serum creatinine ) renal vein thrombosis confirm ultrasound , MRI compute tomography scan . Cardiovascular exclusion : 1 . History active congestive heart failure ( NYHA Functional Classification CHF Class II Class IV ) , . 2 . History know dilate cardiomyopathy leave ventricular ejection fraction ≤40 % , . 3 . Occurrence follow within 3 month screen Visit 1A : i. Unstable angina . ii . Myocardial infarction . iii . Coronary artery bypass graft percutaneous transluminal coronary angioplasty . iv . Transient ischemic attack cerebrovascular disease . v. unstable arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>H.P . Acthar Gel</keyword>
	<keyword>Acthar</keyword>
	<keyword>nephrotic syndrome</keyword>
	<keyword>idiopathic membranous nephropathy</keyword>
	<keyword>proteinuria</keyword>
</DOC>